MedTrace Logo

Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR)

NCT02293733 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 144

Last updated 2014-11-18

No results posted yet for this study

Summary

The purpose of our retrospective study is to describe which circumstances EGFR TKI is continued despite progression according to the usual Response Evaluation CrIteria in Solid Tumours (RECIST) in patients with EGFR activating mutations and acquired resistance to EGFR TKI .We will collect their social and demographic data (age, sex), first Progression Free Survival ( PFS) - from start of EGFR TKI to 1st progression PFS 1- and - from first progression according to RECIST to second progression : PFS2- , Overall Survival (OS) - from diagnosis OS 1 and from first progression OS 2 -, mutational status. We will analyze more closely the mode of progression (site), the therapeutic approach at disease progression. We will define two subgroups: those for whom EGFR TKI was continued at least three months despite progression defined according to RECIST criteria, and those for whom a second-line treatment (chemotherapy without EGFR TKI) was chosen at disease progression. It will be individualized the subgroup of patients in whom it was continued TKI after progression.

Conditions

  • NSCLC Non Small Cells Lung Cancer

Sponsors & Collaborators

  • Groupe Francais De Pneumo-Cancerologie

    lead OTHER

Principal Investigators

  • AULIAC JA Jean-Bernard, MD · Hôpital F. Quesnay 2 bd de Sully 78201 MANTES LA JOLIE

  • GERVAIS RG Radj, MD · Centre François Baclesse 3 avenue du Général Harris 14076 CAEN CEDEX 05

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02293733 on ClinicalTrials.gov